Researchers developed molecules, called splice-switching oligonucleotides (SSOs) that bind to the RNA molecules encoding a protein known as REST. In neuroendocrine tumors, these RNAs are incorrectly spliced together, which supports the cancerous phenotype. When injected into tumors in laboratory mice, SSOs could help restore normal REST function, leading to reduced tumor size. This approach is a promising new tool for treating neuroendocrine tumors that do not respond to conventional therapies.